Literature DB >> 21447733

Use of transporter knockdown Caco-2 cells to investigate the in vitro efflux of statin drugs.

Jibin Li1, Donna A Volpe, Ying Wang, Wei Zhang, Chris Bode, Albert Owen, Ismael J Hidalgo.   

Abstract

The objective of the present study was to determine the efflux transporters responsible for acid and lactone statin drug efflux using transporter knockdown Caco-2 cells. The bidirectional transport was determined in Caco-2 cell monolayers in which the expression of P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), or multidrug resistance associated protein 2 (MRP2) was knocked down by transduction with lentivirus containing human transporter-targeted small hairpin RNAs (shRNAs). Cells transduced with lentivirus containing nontargeted shRNA served as the vector control. Atorvastatin, lovastatin, and rosuvastatin displayed extremely low apical-to-basolateral (A-to-B) transport, which made the P(app,A-B) values too unreliable to calculate the efflux ratio. Thus, transport comparisons were performed using the B-to-A permeability (P(app,B-A)) values. Presented in the order of vector control, P-gp, BCRP, and MRP2 knockdown Caco-2 cells, the P(app,B-A) values (×10(-6), cm/s) were 28.1 ± 1.3, 8.6 ± 2.9, 20.3 ± 1.8, and 21.5 ± 1.6 for atorvastatin; 96.1 ± 7.1, 25.3 ± 3.5, 57.3 ± 9.8, and 48.2 ± 2.3 for fluvastatin; and 14.1 ± 1.9, 4.6 ± 1.7, 5.8 ± 0.7, and 6.6 ± 1.8 for rosuvastatin, respectively. Lovastatin and simvastatin showed no efflux in the vector control or knockdown cell monolayers in either lactone or acid forms. Results indicate that atorvastatin, fluvastatin, and rosuvastatin were transported by P-gp, BCRP, and MRP2. On the other hand, neither the lactone nor the resulting acid of lovastatin and simvastatin was transported by P-gp, BCRP, or MRP2. The current study demonstrated that the transporter knockdown Caco-2 cells are useful tools for studying drug-transporter interactions and should help eliminate some of the ambiguity associated with the identification of drug-transporter interactions based on chemical inhibitors alone.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21447733     DOI: 10.1124/dmd.111.038075

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  27 in total

1.  Glyceollin Effects on MRP2 and BCRP in Caco-2 Cells, and Implications for Metabolic and Transport Interactions.

Authors:  Chukwuemezie Chimezie; Adina Ewing; Chandler Schexnayder; Melyssa Bratton; Elena Glotser; Elena Skripnikova; Pedro Sá; Stephen Boué; Robert E Stratford
Journal:  J Pharm Sci       Date:  2016-01-11       Impact factor: 3.534

2.  Use of different parameters and equations for calculation of IC₅₀ values in efflux assays: potential sources of variability in IC₅₀ determination.

Authors:  Donna A Volpe; Salaheldin S Hamed; Lei K Zhang
Journal:  AAPS J       Date:  2013-12-13       Impact factor: 4.009

3.  Simvastatin interacts synergistically with tipifarnib to induce apoptosis in leukemia cells through the disruption of RAS membrane localization and ERK pathway inhibition.

Authors:  Tamer A Ahmed; John Hayslip; Markos Leggas
Journal:  Leuk Res       Date:  2014-09-16       Impact factor: 3.156

4.  Assessment of Drug-Drug Interaction Potential Between Atorvastatin and LCZ696, A Novel Angiotensin Receptor Neprilysin Inhibitor, in Healthy Chinese Male Subjects.

Authors:  Surya Ayalasomayajula; Wei Pan; Yi Han; Fan Yang; Thomas Langenickel; Parasar Pal; Wei Zhou; Yaozong Yuan; Iris Rajman; Gangadhar Sunkara
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-04       Impact factor: 2.441

5.  Lack of pharmacokinetic interaction between fluvastatin and green tea in healthy volunteers.

Authors:  Shingen Misaka; Osamu Abe; Hideyuki Sato; Tomoyuki Ono; Yayoi Shikama; Satomi Onoue; Hirooki Yabe; Junko Kimura
Journal:  Eur J Clin Pharmacol       Date:  2018-01-24       Impact factor: 2.953

Review 6.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

7.  Case Study 7: Transporters Case Studies-In Vitro Solutions for Translatable Outcomes.

Authors:  Sid Bhoopathy; Chris Bode; Vatsala Naageshwaran; Erica Weiskircher-Hildebrandt; Venkata Mukkavilli; Ismael J Hidalgo
Journal:  Methods Mol Biol       Date:  2021

8.  Anti-HIV and Anti-Hepatitis C Virus Drugs Inhibit P-Glycoprotein Efflux Activity in Caco-2 Cells and Precision-Cut Rat and Human Intestinal Slices.

Authors:  Ondrej Martinec; Martin Huliciak; Frantisek Staud; Filip Cecka; Ivan Vokral; Lukas Cerveny
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

Review 9.  PharmGKB summary: very important pharmacogene information for ABCG2.

Authors:  Alison E Fohner; Deanna J Brackman; Kathleen M Giacomini; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2017-11       Impact factor: 2.089

10.  Prediction of Cyclosporin-Mediated Drug Interaction Using Physiologically Based Pharmacokinetic Model Characterizing Interplay of Drug Transporters and Enzymes.

Authors:  Yiting Yang; Ping Li; Zexin Zhang; Zhongjian Wang; Li Liu; Xiaodong Liu
Journal:  Int J Mol Sci       Date:  2020-09-24       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.